+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peripheral Neuropathic Pain- Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • July 2022
  • Region: Global
  • DelveInsight
  • ID: 4037512
This Peripheral Neuropathic Pain- Pipeline Insight, 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Peripheral Neuropathic Pain: Understanding


Peripheral Neuropathic Pain: Overview


Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain (NP) is not a particular disease, but the clinical condition that is caused by a variety of different diseases and lesions, injuring the nervous system at peripheral or central level, resulting in peripheral NP or central NP, respectively. The nerve damage and subsequent functional and structural neuroplasticity in sensory and autonomic nervous system, may become pathological and maladaptive in certain percentage of patients, and the risk of maladaptation depends on biological, genetic, demographic, and psychosocial factors. The nerve damage induces extensive response in immune system as well, resulting in close interactions between nervous and immune system, and finally neuroinflammation. Neuropathic pain (NP) can result from injury to either the central or peripheral nervous system. Thus, it can be associated with a wide variety of conditions and syndromes. Examples of central nervous system conditions that can have NP include stroke spinal cord injury and multiple sclerosis. Chemotherapy induced neuropathy and diabetic neuropathy are two examples of disorders that can be associated with NP from peripheral nerve injury. The symptoms that these pathologies can generate are diverse and include sensations of burning, tingling, lightning bolts of pain, sharp sensations, unpleasant cold sensations, and electric-like sensations. Chronic NP is slightly more frequent in women (8%) than men (5.7%) in those older than 50 years (8.9%) versus those under 50 years (5.6%). One common cause of chronic NP is diabetic neuropathy. Chronic pain with neuropathic characteristics presents a significant challenge as it is often unresponsive to conventional analgesics. The correct diagnosis and early management of peripheral neuropathic pain not only improve health-related outcomes, but also yield significant cost benefit to society.

“Peripheral Neuropathic Pain- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Peripheral Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain Emerging Drugs Chapters


This segment of the Peripheral Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Neuropathic Pain Emerging Drugs


HSK 16149: Haisco Pharmaceutical Group

HSK16149 is a potent ligand of VGCC α 2 δ subunit with a better therapeutic index. Hence, it could be an effective and safe drug candidate for treating chronic pain. In a study, HSK16149 was found to be a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit. HSK16149 inhibited gabapentin binding to the α 2 δ subunit and was 23 times more potent than pregabalin. In two rat models of neuropathic pain, the minimum effective dose (MED) of HSK16149 was 10 mg/kg, and the efficacy was similar to that of 30 mg/kg pregabalin. Moreover, the efficacy of HSK16149 could persist up to 24 hours post administration at 30 mg/kg, whereas the efficacy of pregabalin lasted only for 12 hours at 30 mg/kg in streptozotocin-induced diabetic neuropathy model, indicating that HSK16149 might be a longer-acting drug candidate. HSK16149 could also inhibit mechanical allodynia in intermittent cold stress model and decrease phase II pain behaviors in formalin-induced nociception model.

ACD 440: AlzeCure

ACD440 is a TRPV1 antagonist that originated in Big Pharma and is based on a strong scientific foundation. The discovery and insight into TRPV1, the biological system that underlies ACD440 and is central to, among other things, temperature regulation and pain, was awarded the Nobel Prize in Physiology or Medicine 2021. The compound has previously undergone Phase I clinical trials, in which both good tolerability and early positive signals of efficacy were observed. The mechanism of action of the project is via TRPV1 receptors, which have a key role in pain signaling, and ACD440 has been shown in preclinical trials to have an effect on both nociceptive and neuropathic pain. The compound has previously undergone extensive preclinical safety studies and since the compound is being developed for local use, systemic exposure can be kept very low, while the concentration of the compound locally can be kept high for maximum analgesic effect.

Peripheral Neuropathic Pain: Therapeutic Assessment


This segment of the report provides insights about the different Peripheral Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Neuropathic Pain


There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II/III include, Haisco Pharmaceutical Group.

Phases

The report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Peripheral Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Neuropathic Pain: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Neuropathic Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Neuropathic Pain drugs.

Peripheral Neuropathic Pain Report Insights

  • Peripheral Neuropathic Pain Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Peripheral Neuropathic Pain Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Peripheral Neuropathic Pain drugs?
  • How many Peripheral Neuropathic Pain drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Neuropathic Pain?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral Neuropathic Pain therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peripheral Neuropathic Pain and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Haisco Pharmaceutical Group
  • AlzeCure
  • Eli Lilly and Company
  • Bayer
  • Eliem Therapeutics
  • SIMR Biotech
  • Aptinyx
  • Lexicon Pharmaceuticals

Key Products

  • HSK 16149
  • ACD 440
  • LY3016859
  • BAY2395840
  • ETX-018810
  • SR419
  • LY3556050
  • LY3526318
  • NYX-2925
  • LX9211


This product will be delivered within 2 business days.

Table of Contents

IntroductionExecutive Summary
Peripheral Neuropathic Pain: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Peripheral Neuropathic Pain- Analytical Perspective
Late Stage Products (Pre-Registration)
  • Comparative Analysis
Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Last Stage Products (Phase II/ III)
  • Comparative Analysis
HSK 16149: Haisco Pharmaceutical Group
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
ACD 440: AlzeCure
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Peripheral Neuropathic Pain Key CompaniesPeripheral Neuropathic Pain Key ProductsPeripheral Neuropathic Pain - Unmet NeedsPeripheral Neuropathic Pain - Market Drivers and BarriersPeripheral Neuropathic Pain - Future Perspectives and ConclusionPeripheral Neuropathic Pain Analyst ViewsPeripheral Neuropathic Pain Key CompaniesAppendix
List of Tables
Table 1 Total Products for Peripheral Neuropathic Pain
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Peripheral Neuropathic Pain
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Haisco Pharmaceutical Group
  • AlzeCure
  • Eli Lilly and Company
  • Bayer
  • Eliem Therapeutics
  • SIMR Biotech
  • Aptinyx
  • Lexicon Pharmaceuticals